

ESPERION[®]

Q2 2025 Earnings Presentation

August 5, 2025

Forward-looking Statements & Disclosures

This investor presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding marketing strategy and commercialization plans, current and planned operational expenses, expected profitability, future operations, commercial products, clinical development, plans for potential future product candidates, financial condition and outlook, including expected cash runway and profitability, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Any express or implied statements contained in this investor presentation that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion’s actual results to differ significantly from those projected, including, without limitation, the net sales, profitability, and growth of Esperion’s commercial products, clinical activities and results, supply chain, commercial development and launch plans, the outcomes and anticipated benefits of legal proceedings and settlements, and the risks detailed in Esperion’s filings with the Securities and Exchange Commission. Any forward-looking statements contained in this investor presentation speak only as of the date hereof, and Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this investor presentation, other than to the extent required by law.

CEO Commentary

“Our second quarter performance highlights the **strength** of our **commercial execution**, growing **adoption** of our **therapies**, and continued progress in **protecting** and **expanding** the long-term value of our portfolio. Our first quarter of **operating income** from ongoing business marks a key milestone towards achieving **sustainable profitability in Q1 2026.**”



Sheldon Koenig

PRESIDENT AND CHIEF
EXECUTIVE OFFICER

Q2 2025: Delivering Strong Momentum

Q2 TOTAL REVENUE

\$82.4M

+12% growth

Q2 U.S. NET PRODUCT SALES

\$40.3M

+42% growth



+10%

Retail Prescription
Equivalents Q/Q



*First Quarter of
Operating Income from
Ongoing Business*




>28,000


Healthcare Providers
Writing Scripts

Expanded Core Marketing Efforts to Reach Statin-Intolerant Patients

What is statin intolerance? Request a Co-Pay Card



Trying to lower your LDL-C (a.k.a. Lipid Lurkers) and reduce your risk of heart attack? If you can't take a statin or take the dose needed, you have options.



The NLA defines **statin intolerance** as experiencing one or more adverse effects from statin therapy that improve or resolve when the dosage is reduced or the medication is discontinued.


Statin intolerance can be partial or complete:

- Partial means you can take a lower dose, but not enough to reach your therapy objective.
- Complete means you can't take any statin at all.

If you struggle with your statin dose, you're not alone.

As many as **5% to 30%** of patients are statin intolerant and **remain at risk for a heart attack**, according to the National Lipid Association.

NEXLIZET contains the only nonstatin* medication proven to reduce the risk of a heart attack in statin-intolerant people.



Are you unable to take your recommended statin dose?

Statins are currently the standard of care to lower bad cholesterol, and not all patients can take a statin or get to the dose they need—often due to statin intolerance symptoms like muscle pain, a common side effect.

Statin intolerance can make managing your cholesterol feel more difficult—especially since higher levels of bad cholesterol can increase your risk of heart attack or stroke.

WHEN PATIENTS CAN'T TAKE A RECOMMENDED STATIN DOSE, WHAT DO YOU DO NEXT?



NEXLIZET* and NEXLETOL* are the **only** FDA-approved products to reduce the risk of MI and coronary revascularization in **primary prevention** and secondary prevention patients with **partial or complete statin intolerance****

*The bempedoic acid component.
**The statin defines partial or complete intolerance as the ability to tolerate chosen dose or dose that is required to achieve the desired lipoprotein, lipoprotein, and complete lipid metabolism on the ability to tolerate any dose or regimen of a statin.

INDICATIONS
NEXLIZET and NEXLETOL are indicated:
- The bempedoic acid component of NEXLIZET and NEXLETOL is indicated for the reduction of the risk of myocardial infarction and coronary revascularization in primary prevention and secondary prevention patients with partial or complete statin intolerance.




facebook

NEXLIZET* (bempedoic acid and ezetimibe) | NEXLETOL* (bempedoic acid) HCP

Sponsored

Could FDA-approved NEXLIZET or NEXLETOL be right for statin-intolerant patients? NEXLIZET PI: bit.ly/3GsgB7U NEXLETOL PI: bit.ly/3KdHwZd



Consider a different option for statin-intolerant patients*

*Partial or complete statin intolerance.

IMPORTANT SAFETY INFORMATION

- NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any of the excipients. Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.
- Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL, may increase blood uric acid levels, which may lead to...

NEXLIZETHCP.com
[See the CV data]

LEARN MORE



When patients can't take a recommended statin dose...

IMPORTANT SAFETY INFORMATION

- NEXLIZET and NEXLETOL are contraindicated in patients with a prior hypersensitivity to bempedoic acid or ezetimibe or any of the excipients. Serious hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported.

Prescribing Information

Can't take a statin? Make NEXLIZET happen!

- **Over 650,000** visits to our consumer statin intolerance website in Q2
- **More than 600,000** click throughs to our HCP statin intolerance site in Q2



Strong engagement underscores the impact of this successful, targeted awareness campaign

Strengthening Access and Driving Growth



Expanded payer coverage and reduced prior authorization requirements



Enhanced reimbursement support resources for patients and providers



Balanced direct and digital marketing approach

Resulted in:

- **10% increase** in total retail prescription equivalents vs. Q1 2025
- Now over **28,000** total HCPs
- **23%** of prescriptions written by physicians with only digital touchpoints
- **38%** of new writer prescriptions were driven by digital only touchpoints
- **Approval rates of more than 80%** following education of 1,100+ target prescribers by our expanded U.S. fields reimbursement team

Reflects growing clinical confidence and broader adoption among statin intolerant patients

Award-Winning Consumer Campaign: Lipid Lurkers

- Tackling the silent threat of high cholesterol through a bold, creative lens
- Introduces **Lipid Lurkers** – mischievous characters that personify the hidden dangers of LDL-C
- Educates and empowers patients to take the next steps after statins
- Drives awareness for **NEXLETOL**[®] (bempedoic acid) and **NEXLIZET**[®] (bempedoic acid and ezetimibe)

Winner of the prestigious Med Ad News Award for
“Best Consumer Digital Campaign”
Finalist for multiple additional awards in 2025



Can't take a statin?

Your Lipid Lurkers (AKA bad cholesterol) may not be low enough and you may be at increased risk of a heart attack.

NEXLIZET[®]
(bempedoic acid/ezetimibe)
180mg/10mg tablets

NEXLIZET contains **THE ONLY NONSTATIN*** FDA approved to lower bad cholesterol and to reduce the risk of heart attack in statin intolerant patients

- LOWERS BAD CHOLESTEROL
- REDUCES RISK OF HEART ATTACK

NEXLIZET* WORKS DIFFERENTLY THAN STATINS AND IS NOT ACTIVE IN SKELETAL MUSCLE.

*The bempedoic acid component.

Ask your healthcare professional **today** how to help **take control** of your Lipid Lurkers

INDICATION
NEXLIZET, a prescription medicine that contains bempedoic acid and ezetimibe, is used in adults along with diet, with or without

• **NEXLIZET can cause serious side effects**, including increased levels of uric acid in the blood, which can lead to gout, a painful joint condition. Call your doctor if you experience severe foot pain, especially in the big joint, warm joints, swelling, tender joints, or



Can't take a statin?

NEED STATIN ALTERNATIVE

© 2025 Esperion Therapeutics, Inc.
All rights reserved. US-UNBR-2500015



Advancing Growth Through Strategic Execution

Consumer Awareness Expansion

- Launch consumer television ad on connected TV (e.g., Hulu, NBC Sports) later this year
- Ad will feature our award-winning Lipid Lurkers and aim to raise awareness of statin intolerance

Growth Drivers and Strategic Outlook

- Continued momentum supported by our marketing and sales initiatives and improving payer dynamics
- Advancing development of triple combination products
- Actively evaluating in-licensing and acquisition opportunities to leverage our commercial infrastructure

IP Protection and Legal Progress

- Reached settlements with three ANDA filers not to market generic versions of NEXLETOL prior to 2040
- Ongoing efforts to further strengthen our IP position

Pipeline Expansion: Novel ACLY Biology

- Advancing IND-enabling studies for new program in primary sclerosing cholangitis (PSC)
- PSC: rare, progressive liver disease with no approved therapies
- Represents ~1B annual market opportunity
- On track to file IND and potentially begin first-in-human studies in 2H 2026



Strategic Partnerships Driving Global Reach


Approved in
40
countries
globally

Maximizing Global Reach Across Key Regions

	Europe	Japan	Asia & South America	Israel	Australia & New Zealand	Canada
Partner	Daiichi Sankyo Europe	Otsuka Pharmaceutical Co., Ltd.	Daiichi Sankyo Co., Ltd.	Neopharm Israel	CSL Seqirus	HLS Therapeutics
Agreement Terms	Tiered royalties and additional sales milestones	Tiered royalties, regulatory, pricing and additional sales milestones	Tiered royalties and additional sales milestones	Tiered royalties and additional milestones	Upfront and near-term milestone payments	Upfront Payment, Milestones and Tiered Royalties
Highlights	<ul style="list-style-type: none"> Launched in many key markets including Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, Netherlands, Slovakia and Czech Republic to date Expanded label approved in EU and UK in May/June '24 	<ul style="list-style-type: none"> Expect approval and National Health Insurance pricing in the second half of 2025 	<ul style="list-style-type: none"> Received regulatory approval to market product (mono & dual) and launched: <ul style="list-style-type: none"> Hong Kong in 2023 Thailand and Macau in 2024 Received regulatory approval to market product (mono) <ul style="list-style-type: none"> Myanmar and Taiwan in 2024 	<ul style="list-style-type: none"> Filed NDA for marketing approval in Q1 2025; approval anticipated in the first half of 2026 	<ul style="list-style-type: none"> Filed marketing application in Australia in July 2025 Expect market approval in Q4 2026 	<ul style="list-style-type: none"> Expect market approval in Q4 2025

Approval and launch in additional territories anticipated in 2025

International Growth Continues at Strong Pace



~555,000 patients through May '25


Note: Numbers are approximate and based on an internal calculation methodology and includes Germany, UK, Austria, Belgium, Switzerland, Italy, Spain, the Netherlands.

© 2025 Esperion Therapeutics, Inc. All rights reserved.

ESPERION[®]

Pipeline Advancement

Proven Science, Innovative Pipeline




LDL-C: low-density lipoprotein cholesterol; CV: cardiovascular; NDA: New Drug Application; IND: Investigational New Drug

High Unmet Need Driving Significant Market Opportunity

PSC: A Rare and Progressive Liver Disease

Diagnosed Prevalence of PSC



>\$1B Annual Market Opportunity Estimate

- **No approved therapies** with proven efficacy to cure or halt PSC progression
- Potential **Orphan Drug Designation & Fast Track Approval**
- Discovery program is **internally developed and wholly-owned globally**

This program highlights the broader potential of ACLY biology

ESPERION[®]

Financial Update

Ben Halladay, Chief Financial Officer

Exceptional Second Quarter Drives Path to Profitability

First Quarter of Operating Income from Ongoing Business in Company's History

Supports Transition to Sustainable Profitability Beginning in Q1 2026

TOTAL REVENUE

\$82.4M

+12% increase

U.S. NET PRODUCT SALES

\$40.3M

+42% increase

COLLABORATION REVENUE

\$42.1M

-7% decrease

+105% increase

Adjusting for one time settlement agreement milestone with DSE received in Q2 2024

Cash and 2025 Guidance

Cash & Cash Equivalents

\$86.1M


Key Financial Data

FY 2025 R&D Guidance	\$55 – 65 M
FY 2025 SG&A Guidance	\$160 – 170 M
FY 2025 OpEx Guidance ¹	\$215 – 235 M


1. Includes ~\$15 million of non-cash stock-based compensation expense

Strong Prescription Demand and Increasing Physician Adoption Continue to Drive Durable Revenue Growth

Quarterly Franchise RPE Trend



Weekly Franchise RPE Trend¹



ESPERION[®]

Important Safety Information

NEXLETOL[®] (bempedoic acid) Important Safety Information

- NEXLETOL is contraindicated in patients with a prior serious hypersensitivity reaction to bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as angioedema, have occurred.
- Hyperuricemia: NEXLETOL may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: NEXLETOL is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLETOL at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of NEXLETOL in $\geq 2\%$ of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- The most common adverse reactions in the cardiovascular outcomes trial for NEXLETOL at an incidence of $\geq 2\%$ and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLETOL when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLETOL.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

See full prescribing information [here](#).

NEXLIZET[®] (bempedoic acid and ezetimibe)

Important Safety Information

- NEXLIZET is contraindicated in patients with a prior hypersensitivity to ezetimibe or bempedoic acid or any of the excipients. Serious hypersensitivity reactions, such as anaphylaxis, angioedema, rash, and urticaria have been reported with ezetimibe or bempedoic acid.
- Hyperuricemia: Bempedoic acid, a component of NEXLIZET, may increase blood uric acid levels, which may lead to gout. Hyperuricemia may occur early in treatment and persist throughout treatment, returning to baseline following discontinuation of treatment. Assess uric acid levels periodically as clinically indicated. Monitor for signs and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate.
- Tendon Rupture: Bempedoic acid, a component of NEXLIZET, is associated with an increased risk of tendon rupture or injury. Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. Discontinue NEXLIZET at the first sign of tendon rupture. Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture.
- The most common adverse reactions in the primary hyperlipidemia trials of bempedoic acid (a component of NEXLIZET) in $\geq 2\%$ of patients and greater than placebo were upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes.
- Adverse reactions reported in $\geq 2\%$ of patients treated with ezetimibe (a component of NEXLIZET) and at an incidence greater than placebo in clinical trials were upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza.
- In the primary hyperlipidemia trials of NEXLIZET, the most commonly reported adverse reactions (incidence $\geq 3\%$ and greater than placebo) observed with NEXLIZET, but not observed in clinical trials of bempedoic acid or ezetimibe, were urinary tract infection, nasopharyngitis, and constipation.
- The most common adverse reactions in the cardiovascular outcomes trial of bempedoic acid (a component of NEXLIZET) at an incidence of $\geq 2\%$ and 0.5% greater than placebo were hyperuricemia, renal impairment, anemia, elevated liver enzymes, muscle spasms, gout, and cholelithiasis.
- Discontinue NEXLIZET when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Because of the potential for serious adverse reactions in a breast-fed infant, breastfeeding is not recommended during treatment with NEXLIZET.
- Report pregnancies to Esperion Therapeutics, Inc. Adverse Event reporting line at 1-833-377-7633.

See full prescribing information [here](#).